Ophthalmic Images Now Available Through the Academy’s IRIS Registry, Organized at Scale by Verana Health’s VeraQ Engine

SAN FRANCISCOVerana Health announced the introduction of ophthalmic images into its VeraQ population health data engine. The approximately 3.5 million images spanning optical coherence tomography (OCT), fundus autofluorescence, color fundus photography, and more. are being integrated into the Academy’s IRIS register. These data are managed by Verana Health via VeraQ, where it is linked to anonymized electronic health record (EHR) data and curated with clinician supervision and artificial intelligence (AI), such as machine learning (ML), to produce variables of quality data and Qdata modules in ophthalmology. These image-derived variables and Qdata modules – presented to the ophthalmic community at the Academy’s annual meeting (AAO 2022) – will be selectively available in the future to academic research institutions participating in the Consortium of IRIS Registry Analysis Centers and life science organizations, respectively.

The IRIS register is one of the largest specialized databases in the world. In his role, Verana Health helps researchers turn this registry data into actionable insights to power medical advances by managing its real data, from ingestion to analysis. Nearly 16,000 clinicians contribute anonymized data to the IRIS registry, which offers over 9 years of longitudinal data on over 75 million patients and 450 million patient visits.

Although the existing EHR data includes important demographic and clinical information, their addition of EHR imaging data – which the Academy leadership noted was only curated outside of the textual EHRs in due to technical and non-patient considerations – adds another valuable dimension. This provides objective structural representations of patients’ eyes that can help confirm diagnoses, track disease progression, and assess the impact of a drug or device intervention.

“The large-scale integration of imaging with existing EHR data will help unlock a whole area of ​​research in ophthalmology that was not possible before,” said Aaron LeeMD, MSc, Associate Professor of Ophthalmology at University of Washington, the first academic medical center to integrate its images into the IRIS registry. “The application of artificial intelligence, such as machine learning and computer vision, to analyze imaging data facilitates deep learning, which could help us discover new associations and biomarkers. of diseases. Ultimately, it could spur research that enables better patient care and better eye health for millions of people.

Research into macular degeneration, geographic atrophy (GA), and the brain/eye connection are among the areas of study where combined EHR and imaging datasets are likely to prove most useful. Verana Health has previously developed proprietary algorithms on linked clinical and imaging datasets and recently presented promising research examining the development of an ML pipeline that automatically uses this combined and curated dataset to diagnose and stage patients with AD. ‘AG.

“The power of linking clinical data from existing EHRs with associated ophthalmic imaging data will help advance the knowledge of academic and life science researchers. This has the opportunity to accelerate clinical trials and improve clinical care, which could ultimately lead to therapeutic advances for patients that help protect vision, brain health, and more,” said Verana Health CEO Soujay Jadhav. “I am particularly excited about the potential implications this has for researchers studying the brain/eye connection and multisystem diseases. As a strategic data and technology partner for specialty medical companies, Verana Health is uniquely positioned to facilitate real-world insights from multiple specialties and data sources, including EHRs, images, and claims, helping to provide a complete view of the patient journey.

In addition to sharing the value of IRIS Registry imaging data with researchers, Verana Health will present four research abstracts at the AAO 2022 meeting:

Real-world safety analysis of an intracanalicular dexamethasone insert using the Academy’s IRIS registry, conducted in collaboration with Eye therapywill be presented by Robert T. ChangMD, on Saturday October 1of 9:40 a.m. to 9:49 a.m. CT in hall A of the Theater and Lounge poster. This study evaluated real-world safety outcomes after cataract surgery with or without DEXTENZA (DEX) treatment using the Academy’s IRIS Registry. This study showed that DEX treatment in cataract surgery patients appears to have a real-world safety profile that is consistent with the product label and may help inform post-marketing safety.

Combining data from the Axon registry and the IRIS registry to compare VA between people with neuromyelitis optica and multiple sclerosis, presented by heather mossMD, PhD, on Saturday October 1of 10:09 a.m. to 10:20 a.m. CT in room S405. This overlap analysis American Academy of Neurology Axon Registry and the American Academy of Ophthalmology IRIS Registry the data showed how anonymized data from two registries allows examination of outcomes entered into the IRIS registry for conditions that are diagnosed more frequently in the Axon registry, demonstrating the utility of multi-registry analysis.

Actual patient demographics and clinical characteristics of an intracanalicular dexamethasone insert using the Academy’s IRIS Registry, an ePoster, produced in collaboration with Eye therapywill be presented on request by Michel Mbagwu, MD. This presentation explores the demographics and clinical comorbidities of real-world cataract surgery patients treated with and without DEX. The results identified relevant demographics and clinical characteristics that can help inform practice patterns.

Clinical Trial Emulation of the CATT Using Data from the IRIS Registry, an on-demand ePoster presented by Durga Borkar, MD, MMCi. This poster presentation shows the process and results of efforts to mimic the pro re nata (prn) arms of the Comparative AMD Treatment Trial (CATT) using anonymized data from a real population. A small percentage of patients met the criteria for the trial, highlighting the potential insights RWD can provide about a broader patient population.

In addition, Verana Health will present a lecture on advances in the diagnosis and treatment of age-related macular degeneration (AMD), and discuss the relevance of measuring MIGS patient-reported outcomes from Verana Health Perspective:

Introducing Eyecelerator: The Future of AMD, Thursday September 29 of 10:45 a.m. to 11:45 a.m. CT in Room E354. Presented by Dr Borkarthis conference is about 1) Verana Health advances in data capabilities through the preservation of diagnostic images and 2) the impact of the IRIS registry on the future diagnosis and treatment of AMD.

Our Eyes on the Patient: Bringing Standardized Patient Experiences into Ophthalmic Device Evaluation and Everyday Clinical Practice, Symposium: SYM53, Saturday October 1of 2:00 p.m. to 3:15 p.m. CT in Room E350.

Verana Health at AAO 2022

Verana Health will exhibit at AAO 2022 in person at Booth 2314 and demonstrate the IRIS Registry Quality Metrics Dashboard for Academy members. The dashboard provides metrics that can help measure the quality of care provided by ophthalmologists, assess opportunities for improving care, and help practices report clinical quality data to the incentive-based payment systems program. on Merit (MIPS). The IRIS registry extracts and submits data for MIPS quality metrics to the Medicare and Medicaid Service Centers (CMS) on behalf of firms that participate in the IRIS register through integrated EHR systems.

Verana Health will also showcase its clinical research solutions, including a new Academy-supported IRIS registry initiative to integrate interested participants into a research network to advance clinical research and data-driven care. This Verana Research Network supports clinical researchers who conduct research at clinical trial sites and physicians who refer patients to trials. A preview of this network opportunity and demonstrations of its Verana Trial Connect (VTC) platform will take place at Verana Health booth 2314 at 11:00 a.m. CT Saturday, October 1 through Monday, October 3.

About Verana Health

Verana Health is a digital health company that elevates the quality of real-world data. Verana Health operates a proprietary real-world data network of more than 20,000 healthcare providers (HCPs) and approximately 90 million anonymized patients, stemming from its strategic data partnerships with the American Academy of Ophthalmology, American Academy of Neurologyand American Urological Association. Using its VeraQ population health data engine, informed by clinicians and enhanced by artificial intelligence, Verana Health transforms structured and unstructured health data into quality data modules, Qdata. Verana Health Qdata helps power analytics solutions and software-as-a-service products for real-world evidence generation, clinical trial enablement, HCP quality reporting, and medical registry data management. Verana Health quality data and information help advance medicine to improve the quality of care and quality of life for patients. For more information, visit www.veranahealth.com.

Contact:

Verana Health Media

Megan Moriarty

Amendola Communications

Such. : 913.515.7530

Email: [email protected]

Norma A. Roth